Compare CSL & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSL | RDY |
|---|---|---|
| Founded | 1917 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 11.6B |
| IPO Year | N/A | N/A |
| Metric | CSL | RDY |
|---|---|---|
| Price | $346.39 | $13.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $386.67 | $16.90 |
| AVG Volume (30 Days) | 353.4K | ★ 1.5M |
| Earning Date | 02-03-2026 | 01-20-2026 |
| Dividend Yield | ★ 1.26% | 0.52% |
| EPS Growth | N/A | ★ 5.58 |
| EPS | ★ 17.56 | 0.76 |
| Revenue | ★ $5,015,100,000.00 | $3,848,694,754.00 |
| Revenue This Year | $0.99 | $6.12 |
| Revenue Next Year | $2.49 | $2.58 |
| P/E Ratio | $19.94 | ★ $17.77 |
| Revenue Growth | 0.14 | ★ 11.09 |
| 52 Week Low | $293.43 | $12.26 |
| 52 Week High | $435.92 | $16.17 |
| Indicator | CSL | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 51.80 |
| Support Level | $348.59 | $12.82 |
| Resistance Level | $365.00 | $13.85 |
| Average True Range (ATR) | 11.14 | 0.23 |
| MACD | -1.02 | 0.06 |
| Stochastic Oscillator | 51.27 | 77.54 |
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.